A

AbbVie

Global biopharmaceutical company developing medicines

Head of Asset in GU - Oncology Clinical Development

Full-TimeUpdated on 10/23/2026
$248k - $471.5k/yr+ Long-term incentive program
Senior, Expert
MD, Doctor of Osteopathic Medicine (DO)
Florham Park, NJ, USA
HybridHybrid; in office Tuesday–Thursday.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A Medical Doctor (M.D.), Doctor of Osteopathy (D.O.), or non-U.S. equivalent of an M.D. degree with a relevant therapeutic specialty in an academic or hospital environment is required.
  • At least 7 years of clinical trial experience in the pharmaceutical industry, academia, or equivalent is required.
  • Ability to run a complex clinical research program independently.
  • Proven leadership skills and ability to bring out the best in others on a cross-functional global team, and ability to lead and manage through influence.
  • Commitment to training and developing junior-level staff, using judgment to ensure an appropriate level of autonomy.
  • Ability to interact externally and internally to support a global scientific and business strategy.
  • Extensive knowledge of clinical trial methodology and regulatory and compliance requirements governing clinical trials, and experience developing clinical strategy and designing study protocols.
  • Excellent oral and written English communication skills.
  • Ability to exercise judgment, address complex problems, and create solutions across multiple projects.
Responsibilities
  • Lead the direction, planning, execution, and interpretation of clinical trials or research activities for one or more clinical development programs; participate in and may lead cross-functional teams to generate, deliver, and disseminate high-quality clinical data supporting product scientific and business strategy.
  • Personally or through a direct report, own the design and implementation of multiple clinical development programs, or one large, complex program, in support of the overall product development plan, using medical and scientific principles and knowledge of compliance and regulatory requirements, customers, markets, business operations, and emerging issues; oversee project-related education of investigators and study site personnel.
  • Lead and mentor clinical study teams; monitor study integrity; review, interpret, and communicate accumulating safety and efficacy data; work with Clinical Operations to ensure agreed study enrollment and timelines for key deliverables; assess and report serious adverse events in assigned protocols according to corporate policy and regulations.
  • Own the design, analysis, interpretation, and reporting of scientific content for protocols, Investigator Brochures, Clinical Study Reports, regulatory submissions and responses, and other program documents.
  • Manage one level of Medical and Scientific Directors, typically 2 to 4, and/or Clinical Scientists, with direct oversight of clinical development activities and/or management of personnel working on other projects; hire, onboard, mentor, train, and support their career development.
  • May chair Clinical Strategy Teams and develop rigorous, cross-functionally aligned and vetted Clinical Development Plans with contingencies and alternative approaches; may supervise matrix team members and serve as the Clinical Research representative providing clinical development and medical expertise to Asset Development Teams and Asset Development Team Leadership Boards.
  • Serve as the in-house clinical expert for one or more molecules and diseases in the therapeutic area; coordinate and lead related scientific activities with internal stakeholders; may contribute to or lead clinical development due diligence or other business development activity; partner with Discovery colleagues on translational strategies as program needs require.
  • Act as clinical lead and solicit opinion-leader interactions related to disease areas; partner with Medical Affairs, Commercial, and other functions, consistent with corporate policies, to incorporate broad cross-functional perspectives into Clinical Development Plans and protocols.
  • Maintain expertise in the therapeutic area through conferences, medical literature, and training; may represent AbbVie at key external meetings.
  • Understand and comply with regulatory requirements for clinical studies and global drug development; serve as a clinical representative in key regulatory discussions.
  • Ensure adherence to Good Clinical Practices, pharmacovigilance standards, standard operating procedures, and other research quality standards.
Desired Qualifications
  • Completion of a residency program is strongly preferred.
  • Completion of a subspecialty fellowship is desirable.
  • Nine or more years of clinical trial experience is preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.